Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Research Report: PBYI
Article By:
Elle Investments
Friday, May 24, 2019 1:41 PM EDT
The lowered 2019 Nerlynx net sales guidance after 1Q19 results puts previous peak sales estimates of $1B+ in doubt. However, given the large sell-off, even with much lower peak sales estimates in the $500M+ range, there is still a lot of upside.
In this article: PBYI
Puma Biotechnology: A Favorable Risk/Reward Bet
Article By:
Elle Investments
Thursday, April 11, 2019 2:31 PM EDT
PBYI dropped about 8% when the EU/Africa licensing deal with Pierre Fabre was announced for potential blockbuster candidate Nerlynx, which is currently approved in the US and EU for HER2+ breast cancer treatment (post-Herceptin).
In this article: PBYI
Week In Review: C-Bridge Raising Another $650 Million For China Healthcare
Article By:
ChinaBio® Today
Saturday, February 3, 2018 4:43 PM EDT
Shanghai's C-Bridge Capital is raising capital for its third healthcare private equity fund with a target of $650 million (see story). Just six months ago, C-Bridge closed its second PE fund at a hard cap of $400 million.